WHO ICTRP trial

An open label study in two parallel groups, each receiving in a randomized, two…

NL-OMON44101 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting

Key facts

Trial ID NL-OMON44101
Public title An open label study in two parallel groups, each receiving in a randomized, two period, cross-over design two single doses of Risperdal® Consta®, to explore the comparative bioavailability of two different batches of Risperdal® Consta® and the intra subject variability of one Risperdal® Consta® batch after intramuscular administration in healthy volunteers
Scientific title An open label study in two parallel groups, each receiving in a randomized, two period, cross-over design two single doses of Risperdal® Consta®, to explore the comparative bioavailability of two different batches of Risperdal® Consta® and the intra subject variability of one Risperdal® Consta®…
Primary sponsor TEVA Pharma
Registry Overview of Medical Research in the Netherlands (NL-OMON)
Recruitment status Not Recruiting
Study type Interventional
Countries The Netherlands
Conditions Schizophrenia;10039628;Schizophrenia
Interventions The study will start with phase 1, an extended screening phase to determine subjects' tolerance to multiple oral doses of 1 mg risperidone (immediate release formulation) once daily for 3 days. During the screening phase standard medical…
Registration date Jun 7, 2016
Target size 48
Secondary IDs 2015-004428-78;NL55433.056.15
Registry page onderzoekmetmensen.nl

At a glance

  • No Results available

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About WHO ICTRP trial registrations

The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.

Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date:

Browse all WHO ICTRP trial registrations